Try ibuprofen plus growth factor and stem-cell mobilizer for X-CGD
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a combination of medicines to help your body release (“mobilize”) stem cells for future treatment in people with X-linked chronic granulomatous disease (X-CGD). If it works well and is safe for you, it may make stem-cell collection easier and more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed genetic diagnosis of X-CGD
- You are between 18 and 45 years old
- You are able to do daily activities at a good level (Karnofsky score above 80)
- Your heart, kidney, liver, and lungs work well enough for the study medicines
- You have no history of blood clots from a clotting disorder (negative thrombophilia test and no prior thrombotic events)
- You can sign informed consent and agree to study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.
This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.
This trial tests a new gene therapy (SGX-001) for chronic granulomatous disease caused by a specific genetic change. The treatment tries to fix the gene in your immune cells so they can fight infections better, and the trial will follow participants for up to 15 years to make sure it's safe and effective.
This study tests a stem cell transplant using a special conditioning regimen to treat chronic granulomatous disease (CGD), a condition that causes repeated infections and inflammation. The transplant aims to replace faulty immune cells with healthy ones from a donor, potentially reducing infections and improving quality of life.
This study tests a gene therapy to treat X-linked severe combined immunodeficiency (X-SCID) without a stem cell transplant from a matched sibling. It aims to improve immune function and reduce infections using your own stem cells modified to carry the correct gene.
This trial tests a new gene therapy for chronic granulomatous disease (CGD), a condition that makes people prone to severe infections. The therapy uses a modified virus to fix the faulty gene in your blood cells, which may help your immune system fight infections better.
Hear when a new Chronic Granulomatous Disease X-linked (X-CGD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.